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OBJECTIVE — Although fenoﬁbrate was associated with less progression of albuminuria in the
Fenoﬁbrate Intervention and Event Lowering in Diabetes (FIELD) study, it is unknown if it has any
effect on renal function. We explored if there were changes in commonly available markers of renal
function during fenoﬁbrate treatment in the FIELD Helsinki cohort excluding statin users.
RESEARCHDESIGNANDMETHODS — Onehundredandseventysubjectswithtype
2 diabetes were randomly assigned to micronized fenoﬁbrate (200 mg/day) or placebo for 5
years. In this substudy, we measured several markers of albumin excretion and renal function.
RESULTS — Afterintensiﬁedtreatment,bloodpressureandfastingglucosedecreasedinboth
groups while A1C remained at 7.2%. Plasma creatinine increased with fenoﬁbrate while urine
creatinine remained comparable between the groups, resulting in signiﬁcant decreases in both
creatinine clearance and estimated glomerular ﬁltration rate (eGFR) by the Modiﬁcation of Diet
in Renal Disease (MDRD)-4 and Cockroft-Gault equations in the fenoﬁbrate group. Cystatin C
increased during fenoﬁbrate treatment. Urinary albumin-to-creatinine ratio and diurnal urine
protein remained unchanged, whereas overnight urinary albumin excretion rate showed minor
decreases in both groups.
CONCLUSIONS — We report concomitant decreases in creatinine clearance and eGFR by
fenoﬁbrate. These changes complicate the clinical surveillance during fenoﬁbrate treatment. We
couldnotdemonstratethebeneﬁcialeffectsoffenoﬁbrateonalbuminexcretion.Anovelﬁnding
is the increase of cystatin C in type 2 diabetic patients during fenoﬁbrate treatment. The clinical
relevance of the changes needs to be assessed in a long-term outcome study of renal function.
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D
iabetic nephropathy is associated
with a marked increase of cardio-
vascular disease (CVD) (1,2). Part
of this risk has been explained by con-
comitant dyslipidemia, which is further
aggravated in patients who develop dia-
betic nephropathy. This in particular is
reﬂected in decreased HDL cholesterol
and increased triglyceride (TG) levels. In-
terestingly,hypertriglyceridemiaseemsto
be associated with the development and
the progression of nondiabetic (3,4) as
well as diabetic kidney disease (5,6).
Fibrates are peroxisome proliferator–
activated receptor  agonists, designed to
decreaseTGsandLDLcholesterolandin-
crease HDL cholesterol. Fenoﬁbrate has
been shown to reduce the progression of
microalbuminuria in patients with type 2
diabetes in the Fenoﬁbrate Intervention
and Event Lowering in Diabetes (FIELD)
study and the Diabetes Atherosclerosis
Intervention Study (DAIS) (7,8). In these
studies, data on albuminuria were ana-
lyzedusingachangebetweendifferental-
buminuria categories as an indicator of
progression or regression. More patients
showed regression to a lower level and
fewer patients showed progression to a
higher level of albuminuria in the fenoﬁ-
brate group. Such categorical analysis is
sensitive to changes in the variance of the
data, and thus the results should be inter-
preted cautiously. In fact, the absolute val-
uesofalbuminexcretionrate(AER)didnot
change during the DAIS (15.2 vs. 12.7 g/
min, P  not signiﬁcant [NS]).
Plasma creatinine levels seem to in-
crease with the use of ﬁbrates. The exact
mechanismforthisincreaseisnotknown.
In a 2-week study in dyslipidemic sub-
jects (n  13), there was no effect of
fenoﬁbrate on creatinine clearance, ex-
plained by an increased urinary excretion
of creatinine and, thus, no subsequent
change in the creatinine clearance (9). A
recent study (10), however, reported that
the urinary excretion of creatinine re-
mained unchanged even though para-
aminohippurate clearance was decreased
and cystatin C was increased. Thus, avail-
able data are rather confusing and do
not address the important question of
whether the fenoﬁbrate-induced in-
crease in plasma creatinine is or is not
detrimental.
In this prespeciﬁed FIELD Helsinki
substudy, we used several markers of al-
buminuria and renal function, including
cystatin C, to further elucidate the exist-
ing controversy of fenoﬁbrate therapy.
RESEARCH DESIGN AND
METHODS— The FIELD study de-
sign has been described in detail (11).
Brieﬂy, men and women aged 50–75
years with type 2 diabetes, with or with-
out prior coronary heart disease, were el-
igible using the following lipid criteria:
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plus either S-TGs (1.0–5.0 mmol/l) or S-
cholesterol–to–HDL cholesterol ratio
over 4. Patients with hepatic or renal (S-
creatinine 130 mol/l) dysfunction,
gallstones, lipid-lowering medication, cy-
closporin,alcoholabuse,andothersevere
mental or physical illnesses were ex-
cluded. Patients were randomly assigned
to receive in a double-blind design either
placebo or micronized fenoﬁbrate (200
mg daily) for 5 years. In randomization,
patientswerestratiﬁedwithinthecountry
stratumforprognosticfactorssuchasage,
sex, previous myocardial infarction, lipid
levels, and urinary albumin concentra-
tion. A total of 270 type 2 diabetic pa-
tients were recruited to the FIELD study
at the Helsinki Centre (Finland). Of these
patients,239volunteeredtoparticipatein
this substudy and 228 were randomized
to the placebo or fenoﬁbrate group (Fig.
1). There were two deaths and 12 serious
adverse events in the placebo group and
ﬁve deaths and 15 serious adverse events
inthefenoﬁbrategroup.Weexcludedpa-
tients who had statin added to their med-
ication during the study course since this
was considered a confounding factor. We
further excluded from the analysis one
patient who developed diabetic nephrop-
athyandovertproteinuria(3g/24h)early
inthestudyandwasthusaclearoutlierin
our study population. Consequently, 170
patientswereeligiblefortheanalysis(pla-
cebo group  62 men and 21 women,
fenoﬁbrate group  63 men and 24
women). All patients signed informed
consent forms. The ethics committee of
the Helsinki University Central Hospi-
tal approved the substudy protocol.
This analysis and report have been pre-
pared independent of the FIELD Study
Group.
Laboratory analyses
Baseline examinations were performed
during the placebo run-in period of the
FIELD study before any fenoﬁbrate inter-
vention. Blood samples were obtained af-
ter an overnight fast. Serum and EDTA
plasma were separated by centrifugation
and stored at 80°C until analyzed. Lip-
ids were measured in lipoprotein frac-
tions isolated by ultracentrifugation.
Enzymatic colorimetric assays were used
to measure cholesterol (Unimate 7
CHOL, Hoffman-La Roche, Basel, Swit-
zerland, for baseline samples and later
ABX Diagnostics Cholesterol and ABX
Pentra Cholesterol, HORIBA ABX, Mont-
pellier,France)andTG(Unimate7TRIG,
Hoffman-La Roche, for baseline samples
and later ABX Diagnostics Triglycerides
and ABX Pentra Triglycerides, HORIBA
ABX) concentrations in whole sera or li-
poprotein fractions using a Cobas Mira
automatic analyzer (Hoffman-La Roche).
Plasma glucose concentrations were ana-
lyzed by a glucose dehydrogenase
method(Precision-GBloodGlucoseTest-
ingSystem;Abbott,AbbottPark,IL).A1C
wasmeasuredusingacommerciallyavail-
able kit (DCA 2000 Analyzer; Bayer Di-
agnostics, Tarrytown, NY).
Serum/plasma/urine creatinine was
measuredusingtheJaffemethodandlater
using an enzymatic method in the labora-
tory of Helsinki University Central Hos-
pital. Samples were randomly selected to
perform parallel analyses with the Jaffe
and enzymatic methods. The values from
the two methods were highly correlated
with R
2  0.977, and their relationship
was formulated as serum creatinine
(mol/l, enzymatic method)  1.07 
serum creatinine (mol/l, Jaffe method) 
21. Due to 15% lower levels of creati-
nine with the enzymatic method, a con-
version factor of 0.85 was used for
values measured with the Jaffe method.
Thetimedovernighturinesampleswere
analyzedforalbuminconcentrationbyan
immunoturbidimetric method. At base-
line, AER was collected during 3 consec-
utive nights, and the median of these
results was used in the analysis. At the
2nd year and the 5th year, an additional
AER was collected. The patients collected
a 24-h urine sample at each study visit,
and urinary protein excretion rate (mea-
sured by a turbidimetric benzetoniumchlo-
ridemethod)andcreatinineclearancewere
calculated from the same sample. The
eGFR was calculated both by Cockroft-
Gault equation and MDRD-4. The eGFR
estimates and the calculated creatinine
clearance were normalized to body sur-
face area by the DuBois formula. We
also used the data on ACR, which was
determined from a spot sample in the
main FIELD study. Cystatin C was mea-
sured by an immunoprecipitation
method (Thermo Fisher Scientiﬁc, Van-
taa, Finland).
Statistical analysis
The statistical analysis was performed us-
ing SPSS 12.0 (SPSS, Chicago, IL) and
ConﬁdenceIntervalAnalysis2.1.2(www.
som.soton.ac.uk/cia/). Most of the vari-
ables were non-normally distributed, and
their results are shown as median (
SEM) in Fig. 2 and median with inter-
quartile range in Tables 1 and 2.
For normally distributed variables,
mean ( SEM) is used in Fig. 2 and
mean 	 SD is used in the tables. We used
repeated-measures ANOVA with log-
transformed values or the Mann-Whitney
U test to compare changes between the
treatment groups and Wilcoxon signed-
rank test for matched pairs to compare
the changes within the groups. When test-
ing variables of renal function, we included
covariates of glucose, blood pressure, LDL
cholesterol,andTGstotheANOVAmodel.
Qualitative variables are presented as N
(%), and their changes are compared with
the 2  2 likelihood ratio test for transition
probability matrices (www.kttl.helsinki.ﬁ/
sarna/Stats/LRtest2x2.xls) or 

2 test. Corre-
lations were studied using Spearman
Figure 1—Consort ﬂow of the study patients.
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was considered signiﬁcant in all analyses.
RESULTS
Characteristics of patients
The mean age of subjects was 61.3 	 6.7
yearsintheplaceboand62.5	6.3yearsin
the fenoﬁbrate groups (NS). Median dura-
tion of diabetes was 5 years (2–10) in the
placebo group and 6 years (3–11) in the
fenoﬁbrate group. The majority of the pa-
tients were nonsmokers (42%) or former
smokers (43%), and there were no signiﬁ-
cant differences between the groups during
thestudy.AhistoryofCVDwasreportedby
25% in the placebo group and 33% in the
fenoﬁbrategroup(PNS).Inbothgroups,
13% of the patients had retinopathy. Fast-
ing serum glucose values decreased slightly
in both groups with no change in A1C
(Table 1 and supplemental Table 1 in the
online appendix, available at http://care.
diabetesjournals.org/cgi/content/full/dc09-
0621/DC1). The use of antihypertensive
treatment increased in both groups, and
systolic blood pressure was decreased in
both groups (Table 1). Our study cohort
was similar to the entire Finnish FIELD
study cohort and had a greater proportion
of men and patients with preexisting CVD
compared with the entire FIELD study co-
hort. The use of -blockers, diuretics, aspi-
Figure 2—Creatinine levels in plasma (P-creatinine) and urine (U-creatinine) and markers of renal function during the study in placebo and
fenoﬁbrate groups.  , baseline; , 2nd year; f, 5th-year data (median). The change (
) during the study is expressed as total change for P- and
U-creatinine and as annual change for the markers of renal function. The changes have been compared with the Mann-Whitney U test. CG,
Cockroft-Gault.
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more common in our cohort compared
with the entire FIELD study cohort (data
not shown).
Markers of renal function and
albuminuria
Plasma creatinine increased during feno-
ﬁbrate treatment (Fig. 2A), which was
similar to the main FIELD study. How-
ever, urine creatinine levels remained
comparable between the treatment
groups (Fig. 2B). This obviously resulted
in a decrease in calculated creatinine
clearance and eGFR (Fig. 2C–E)i nt h e
fenoﬁbrate treatment group. There were
no differences in 24-h urine protein ex-
cretion, AER, or ACR between the treat-
ment groups at study close-out (Table 2).
Cystatin C increased in the fenoﬁ-
brate treatment group by 14.1% during
the study, compared with the 3.6% in-
crease in the placebo group (P  0.001).
Of the albuminuria markers, AER de-
creased in both groups whereas ACR re-
mained stable.
CONCLUSIONS— Ourstudyshowed
that fenoﬁbrate reduces several measures
of renal function to a greater extent than
placebo.
In addition, our study showed that
long-term fenoﬁbrate treatment had no ef-
fect on albumin excretion rate. This ﬁnding
is in agreement with the lack of changes in
the mean values of AER attributable to fe-
noﬁbrate in the DAIS. In the FIELD study,
the allegedly beneﬁcial renal outcome was
based on 2.6% more patients allocated to
fenoﬁbrate than placebo regressing or not
progressing in a categorized albuminuria
variable (P  0.002). This beneﬁt is rather
modest,andtheclinicalrelevanceshouldbe
evaluated in a long-term outcome study of
renal function.
In the placebo group, systolic and di-
astolic blood pressure decreased by 2 and
8 mmHg, respectively, and in the fenoﬁ-
brate group by 6 and 8 mmHg, respec-
tively. These changes in blood pressure
may explain the decrease in AER in both
groups.Furthermore,theincreaseduseof
renin-angiotensin system blockers in
bothgroupsmayhavehadnephroprotec-
tiveeffectsbeyondarterialbloodpressure
lowering. It should also be recognized
thatglycemiccontroldidnotworsendur-
ing our 5-year study. These variables, to-
gether with TGs and LDL cholesterol,
were included in the repeated-measures
ANOVA and were found not to account
for the changes in renal function. Overall,
these factors may explain the modest an-
nual reduction of eGFR seen in the pla-
cebo group.
Table 1—Characteristics of the patients at baseline and at the 5th year
Placebo Fenoﬁbrate
P§ Baseline 5th year Baseline 5th year
n 83 83 87 87
BMI (kg/m
2) 29.7 (26.8–33.0) 29.5 (26.6–32.9) 29.1 (26.3–32.5) 28.6 (26.3–33.4) NS
Glucose (mmol/l) 7.7 (6.5–8.7) 7.1 (6.0–8.8) 7.9 (6.8–9.1) 7.2 (6.0–8.6)‡ NS
A1C (%) 7.0 (6.3–8.1) 7.0 (6.4–7.7) 7.2 (6.6–8.0) 7.3 (6.6–8.1) NS
sBP (mmHg) 140 (132–150) 138 (126–148)‡ 142 (134–152) 136 (126–142)* NS
dBP (mmHg) 87 	 98 0 	 9* 88 	 97 8 	 10* 0.047
S-cholesterol (mmol/l) 4.9 	 0.7 5.0 	 0.6 5.2 	 0.7 4.3 	 0.8* 0.001
LDL cholesterol (mmol/l) 3.0 	 0.6 3.0 	 0.6 3.3 	 0.6 2.7 	 0.7* 0.001
TG (mmol/l) 1.7 (1.3–2.1) 1.6 (1.2–2.2) 1.5 (1.1–2.2) 1.1 (0.8–1.7)* 0.001
HDL cholesterol (mmol/l) 1.1 (1.0–1.3) 1.2 (1.0–1.4)* 1.1 (1.0–1.4) 1.1 (1.0–1.4) NS
Data are means 	 SD or median (interquartile range). Between baseline and 5th year within each group, P values with Wilcoxon signed-rank test for two related
variables. *P  0.001, ‡P  0.05, §P value from the repeated-measures ANOVA. dBP, diastolic blood pressure; sBP, systolic blood pressure.
Table 2—Markers of albuminuria and renal function at baseline and at the 5th year
Placebo Fenoﬁbrate
P§ Baseline 5th year Baseline 5th year
n 83 83 87 87
P-creatinine (mol/l) 73 (66–78) 75 (63–85) 73 (68–85) 87 (75–101)* 0.001
U-creatinine (mmol/24 h) 13.0 (10.8–15.5) 12.9 (10.0–15.5) 13.2 (10.8–15.6) 14.0 (10.0–16.4) NS
Creatinine clearance (ml/min per 1.73 m
2) 108 (95–119) 104 (89–127) 102 (87–118) 95 (77–112)* 0.027
eGFR-CG (ml/min per 1.73 m
2) 95 (83–109) 90 (75–108) 93 (80–104) 76 (59–89)* 0.001
eGFR-MDRD (ml/min per 1.73 m
2) 95 	 15 95 	 23 91 	 16 78 	 20* 0.001
Cystatin C (mg/l) 0.85 	 0.13* 0.91 	 0.17 0.92 	 0.17 1.05 	 0.25* 0.001
AER (g/min) 6.5 (5–11) 4 (2–11)‡ 6 (4–12) 4 (2–13) NS
dU-Prot (mg/day) 105 (82–190) 100 (70–150) 123 (78–184) 110 (73–190) NS
ACR (mg/mmol) 1.0 (0.7–2.3) 1.1 (0.4–2.9) 1.1 (0.6–2.8) 1.0 (0.0–3.3) NS
CPK (u/l) 92 (61–134) 98 (70–150) 84 (60–133) 84 (55–115) 0.05
Data are means 	 SD or median (interquartile range). Between baseline and 5th year within each group, P values with Wilcoxon signed-rank test for two related
variables. *P  0.001, ‡P  0.05, §P value from the repeated-measures ANOVA, except for AER for which Mann-Whitney U test was used to compare relative
changes from baseline to 5th year between the groups. CG, Cockroft-Gault; CPK, creatine phosphokinase; dU-Prot, 24-h urine protein excretion; P-creatinine,
plasma creatinine; U-creatinine, urine creatinine.
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fenoﬁbrate is a well-established phe-
nomenon. In contrast, the reduction in
renal function has been previously ob-
served as a decrease of para-aminohip-
purate clearance and an increase of
cystatin C in nondiabetic subjects (10).
Sinceurinarycreatininelevelsremained
unchangedinbothstudies,therewasan
obvious reduction in creatinine clear-
ance. The MDRD-4 and Cockroft-Gault
estimates express variability and tend to
underestimate renal function in sub-
jects with relatively normal renal func-
tion. In these patients, creatinine
clearance is a more reliable measure of
renal function. As cystatin C is consid-
ered the best marker of renal function
(12,13), we used it as a creatinine-
independent marker of renal dysfunc-
tion during fenoﬁbrate treatment. We
observed a 14% increase of cystatin C
levels in the fenoﬁbrate group, suggest-
ing impairment of renal function.
It has been suggested that ﬁbrates
increase the production of creatinine
(9) with no adverse effect on renal func-
tion. This seems unlikely since an in-
crease of creatinine excretion has not
been observed (10), which was con-
ﬁrmed in our study. Thus, we cannot
exclude the option that the increase of
creatinine iscaused by the decrease in cre-
atinine clearance. Another hypothetical op-
tion is that fenoﬁbrate might have an
inhibitory effect on the excretion of creati-
nine via the kidneys, requesting higher
blood concentration of creatinine to main-
tain normal excretion. Finally, fenoﬁbrate
may increase the ﬂow of creatinine from
the muscle. If fenoﬁbrate increases creati-
nineoutﬂowfromthemuscle,muscledam-
age cannot be ruled out. However, creatine
phosphokinase levels were lower in the fe-
noﬁbrate group in this study. Likewise, in-
creased ﬂux of creatinine from muscle
shouldbereﬂectedinincreasedexcretionof
creatinine,whichwasnotseeninthisstudy.
This study was a prespeciﬁed FIELD
Helsinki substudy addressing renal func-
tion using several markers but not an in-
tentiontotreatanalysisasseveralpatients
were excluded. In this substudy, direct
measuresofGFRcouldnotbeuseddueto
multiple visits and a cumbersome study
protocol. However, the size of our study
cohort gives enough statistical power de-
spite potential day-to-day variations in
the measured variables. The strength of
our study is that all used parameters of
albumin excretion and renal function
showed parallel results in the fenoﬁbrate
group.
Inconclusion,ourresultsdonotsup-
portthebeneﬁtsoffenoﬁbrateonthepro-
gression of albuminuria. Available data
do not allow us to conclude whether the
fenoﬁbrate-inducedincreaseincreatinine
and cystatin C are relevant for the prog-
noses of these patients, but obviously the
changes in the estimates of eGFR impair
the follow-up of renal function in clinical
practice. The results of the lipid-lowering
arm of the Action to Control Cardiovas-
cular Risk in Diabetes (ACCORD) trial
may clarify the issue (14). Currently, the
use of fenoﬁbrate for cardiovascular pro-
tection should be considered in the con-
textoftheincreasesofbothcreatinineand
cystatin C.
Acknowledgments— This study was sup-
portedbygrantsfromtheFolkha ¨lsanResearch
Foundation (to C.F., P.-H.G.), the Finnish Di-
abetes Association (to E.S.L., M.-R.T.), the
Jenny and Antti Wihuri Fund (to E.S.L.), the
Helsinki University Central Hospital Research
Foundation (to C.F., A.H., E.S.L., P.-H.G.,
M.-R.T.), the Aarne Koskelo Foundation (to
A.H.),theAarneandAiliTurunenFoundation
(to A.H.), and the Sigrid Juselius Foundation
(to M.-R.T.). The FIELD Study was supported
by a grant from Laboratoires Fournier SA, Di-
jon, France.
E.L., after participating in the FIELD Hel-
sinki substudy, reports being appointed by Eli
LillyFinlandasclinicalresearchphysicianand
isafull-timeemployeeofEliLilly,whichman-
ufactures and markets medicine for diabetes
butnotlipiddisorders.M.-R.T.reportshaving
received honoraria and lecture or consulting
fees from AstraZeneca, Kowa, Laboratoires
Fournier,MerckSharp&Dohme,Novartis,and
sanoﬁ-aventisandhavingreceivedresearchsup-
port from Eli Lilly, sanoﬁ-aventis, and Takeda.
Nootherpotentialconﬂictsofinterestrelevantto
this article were reported.
We thank all patients who participated in
this study. We thank Hannele Hilden, Nina
Hyva ¨rinen, Tuija Mård, Virve Naatti, Helina ¨
Perttunen-Nio, Anne Salo, and Aija Helin for
their excellent technical assistance and Seppo
Sarna for statistical advice. We gratefully ac-
knowledge Anthony Keech and the personnel
attheClinicalTrialsCentreattheUniversityof
Sydney, Australia, for the organization of the
main FIELD study.
References
1. Watkins PJ. Cardiovascular disease, hy-
pertension, and lipids. BMJ 2003;326:
874–876
2. WeinerDE,TighiouartH,StarkPC,Amin
MG, MacLeod B, Grifﬁth JL, Salem DN,
Levey AS, Sarnak MJ. Kidney disease as a
risk factor for recurrent cardiovascular
disease and mortality. Am J Kidney Dis
2004;44:198–206
3. MuntnerP,CoreshJ,SmithJC,EckfeldtJ,
Klag MJ. Plasma lipids and risk of devel-
opingrenaldysfunction:theatherosclero-
sis risk in communities study. Kidney Int
2000;58:293–301
4. Tozawa M, Iseki K, Iseki C, Oshiro S,
Ikemiya Y, Takishita S. Triglyceride, but
not total cholesterol or low-density li-
poprotein cholesterol levels, predict de-
velopment of proteinuria. Kidney Int
2002;62:1743–1749
5. Colhoun HM, Lee ET, Bennett PH, Lu M,
Keen H, Wang SL, Stevens LK, Fuller JH.
Risk factors for renal failure: the WHO
Multinational Study of Vascular Disease
in Diabetes. Diabetologia 2001;44(Suppl.
2):S46–S53
6. Cusick M, Chew EY, Hoogwerf B, Agro ´n
E, Wu L, Lindley A, Ferris FL 3rd; Early
Treatment Diabetic Retinopathy Study
Research Group. Risk factors for renal re-
placement therapy in the Early Treatment
Diabetic Retinopathy Study (ETDRS),
Early Treatment Diabetic Retinopathy
StudyReportNo.26.KidneyInt2004;66:
1173–1179
7. Keech A, Simes RJ, Barter P, Best J, Scott
R, Taskinen MR, Forder P, Pillai A, Davis
T, Glasziou P, Drury P, Kesa ¨niemi YA,
Sullivan D, Hunt D, Colman P, d’Emden
M, Whiting M, Ehnholm C, Laakso M;
FIELDstudyinvestigators.Effectsoflong-
term fenoﬁbrate therapy on cardiovascu-
lar events in 9795 people with type 2
diabetes mellitus (the FIELD study): ran-
domised controlled trial. Lancet 2005;
366:1849–1861
8. Ansquer JC, Foucher C, Rattier S, Taski-
nen MR, Steiner G; DAIS Investigators:
Fenoﬁbrate reduces progression to mi-
croalbuminuria over 3 years in a placebo-
controlledstudyintype2diabetes:results
from the Diabetes Atherosclerosis Inter-
vention Study (DAIS). Am J Kidney Dis
2005;45:485–493
9. Hottelart C, El Esper N, Rose F, Achard
JM, Fournier A. Fenoﬁbrate increases cre-
atininemia by increasing metabolic pro-
duction of creatinine. Nephron 2002;92:
536–541
10. Ansquer JC, Dalton RN, Causse E, Crimet
D, Le Malicot K, Foucher C. Effect of fe-
noﬁbrate on kidney function: a 6-week
randomized crossover trial in healthy
people. Am J Kidney Dis 2008;51:904–
913
11. Field Study Investigators. The need for a
large-scale trial of ﬁbrate therapy in dia-
betes: the rationale and design of the
Fenoﬁbrate Intervention and Event Low-
ering in Diabetes (FIELD) study [ISRCTN
64783481]. Cardiovasc Diabetol 2004;
3:9
12. Stevens LA, Coresh J, Schmid CH, Feld-
man HI, Froissart M, Kusek J, Rossert J,
Forsblom and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 219Van Lente F, Bruce RD 3rd, Zhang YL,
Greene T, Levey AS. Estimating GFR us-
ing serum cystatin C alone and in combi-
nation with serum creatinine: a pooled
analysis of 3,418 individuals with CKD.
Am J Kidney Dis 2008;51:395–406
13. RoosJF,DoustJ,TettSE,KirkpatrickCM.
Diagnostic accuracy of cystatin C com-
pared to serum creatinine for the estima-
tion of renal dysfunction in adults and
children: a meta-analysis. Clin Biochem
2007;40:383–391
14. ACCORD Study Group, Buse JB, Bigger
JT, Byington RP, Cooper LS, Cushman
WC, Friedewald WT, Genuth S, Gerstein
HC,GinsbergHN,GoffDCJr,GrimmRH
Jr, Margolis KL, Probstﬁeld JL, Simons-
Morton DG, Sullivan MD. Action to Con-
trol Cardiovascular Risk in Diabetes
(ACCORD) trial: design and methods.
Am J Cardiol 2007;99:21i–33i
Renal effects of fenoﬁbrate in type 2 diabetes
220 DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 care.diabetesjournals.org